BioSpace News Archive

Pia MacDonald, MPH, Ph.D., an infectious disease epidemiologist at RTI International, a nonprofit research institute, is available for media interviews on the future trajectory of the COVID-19 pandemic, the importance of vaccinations, and the impact of Delta variant and other virus variants on reaching herd immunity moving into the fall.

A new study to be presented this week at Heart Rhythm 2021 and recently published in the American Journal of Cardiology1 shows use of the KardiaMobile 6L device results in a reduction of in-person healthcare utilization.

Transcat, Inc., a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professional grade handheld test, measurement and control instrumentation, reported financial results for its first quarter ended June 26, 2021 of fiscal year 2022, which ends March 26, 2022.

HUTCHMED Limited and AstraZeneca PLC have initiated a Phase II study of ORPATHYS®, an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase, in patients with advanced or metastatic MET amplified gastric cancer or adenocarcinoma of the gastroesophageal junction.

The ASC22 Phase IIb study is a randomized, single-blind, placebo-controlled, multi-center clinical trial in China which evaluates the safety and efficacy of treating patients with CHB for 24-week treatment of 1 mg/kg or 2.5 mg/kg ASC22 or matching placebo given once every two weeks in combination with NAs.

Senior management of Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12 at 3:30 p.m. ET and the Morgan Stanley Virtual Global Healthcare Conference on Friday, September 10 at 9:30 a.m. ET. Both events are virtual conferences.

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter ended June 30, 2021.

On July 27, 2021, Venus Medtech Inc., a leading provider of comprehensive interventional heart valve therapy solutions in China, and its controlling subsidiary Renaly Ltd., announced that Professor Martin B. Leon, MD, a pioneer in the field of interventional cardiovascular devices, has been appointed as the Global Principal Investigator for its new-generation renal artery denervation system.

Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021.

BioFlyte, a biodetection company with a revolutionary new class of fieldable biological threat collection, detection, and identification solutions, today announced the formation of a Scientific Advisory Board (SAB).